FindTrial
Sign In

We are measuring biomarker like suPAR (soluble urokinase plasminogen activated receptor) and comparing the outcome in Type 2 diabetes mellitus patients undergoing Coronary artery bypass grafting (CABG) ?

Does measurement of biomarker like suPAR (soluble urokinase plasminogen activated receptor) help reduce mortality in Type 2 diabetes mellitus patients undergoing Coronary artery bypass grafting (CABG) ?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045859
Enrollment
96
Registered
2022-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery Health Condition 2: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: Measurement of different biomarkers: We are measuring diiferent biomarkers including soluble urokinase plasminogen activated receptor and see their role in prognosis in On pump CABG pat

Sponsors

All India Institute of Medical SciencesNew Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 At least 18 years of age or older 2 Known case of T2DM 3 American Society of Anesthesiologists (ASA) physical status I to IV

Exclusion criteria

Exclusion criteria: 1 Patients below 18 years of age 2 Patients undergoing another procedure alongwith CABG 3 Redo cardiac surgery, redo CABG 4 Emergency CABG , Off- pump CABG 5 Patients with an active ongoing infection � Patients on cancer therapy � Severe liver disease � Allergies � Connective tissue disorders � Alcohol or other abuse � Refusal of consent for participation

Design outcomes

Primary

MeasureTime frame
ââ?¬Â¢ To evaluate whether measurement of suPAR levels help in prognostication in patients with Type 2 Diabetes Mellitus undergoing CABG surgeryTimepoint: 24 hours and 48 hours—

Secondary

MeasureTime frame
1. Duration of mechanical ventilation 2. Length of ICU stay 3. Vasoactive Ionotropic score 4. Post operative adverse events 5. Mortality Timepoint: 48 hours—

Countries

India

Contacts

Public ContactPoonam Malhotra Kapoor

All India Institute of Medical Sciences,New Delhi

drpoonamaiims@gmail.com09971000741

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026